HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Allergic contact dermatitis to pimecrolimus.

Abstract
Pimecrolimus suppresses the proinflammatory cytokine production of cutaneous T and mast cells (1). It is used to treat atopic dermatitis and is the active ingredient in the topical formulation pimecrolimus 1.0% cream (Elidel, Novartis Pharma AG, Basel, Switzerland).
AuthorsPeter Saitta, Ronald Brancaccio
JournalContact dermatitis (Contact Dermatitis) Vol. 56 Issue 1 Pg. 43-4 (Jan 2007) ISSN: 0105-1873 [Print] England
PMID17177710 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Dermatologic Agents
  • pimecrolimus
  • Tacrolimus
Topics
  • Aged
  • Dermatitis, Allergic Contact (etiology)
  • Dermatologic Agents (adverse effects)
  • Female
  • Humans
  • Tacrolimus (adverse effects, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: